ArticleClinical, cosmetic and investigational dermatology2026
Enhanced Efficacy of Post-Procedural Skin Care: A Double-Blind, Randomized, Vehicle-Controlled, Split-Face Clinical Study Assessing a Novel Neuropeptide Serum Following Botulinum Toxin Injection.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Botulinum toxins type-A (BTX-A) including onabotulinumtoxinA (Botox Cosmetic Purpose: Optimizing post-BXT-A skincare is crucial for maximizing results and overall skin health. This randomized double-blind vehicle-controlled, split-face study investigated a novel neuropeptide serum designed to complement BTX-A injections in a post-procedural setting. Methods: This is a 10-week, split-face, double-blind, vehicle-controlled randomized study designed to assess the efficacy and tolerability of a topical neuropeptide serum compared to vehicle control as pre- and post-procedural skincare around onabotulinumtoxinA injections in subjects with mild-to-moderate facial lines, facial wrinkles, and rough skin. At pre-treatment, subjects applied either neuropeptide serum or vehicle to one-half of the face randomized in conjunction with moisturizer, cleanser and sunscreen for 14 days. At baseline, subjects received on-label onabotulinumtoxinA injections for glabella and lateral canthal lines, post-injection subjects continued their randomized skincare regimen. Clinical efficacy live grading was assessed at pre-treatment, baseline, weeks 2, 4 and 8. Tolerance and subject self-assessments were conducted during the study. Results: The novel neuropeptide serum demonstrated statistically significant improvement (p < 0.05) compared to vehicle in 18 facial attributes assessed by the clinical dermatologist, including forehead wrinkles, global fine lines, smoothness and radiance at 8 weeks post BTX-A injection. Additionally, no tolerability concerns were observed by either the investigator or subjects. Compared to vehicle, the neuropeptides serum's statistical benefits can be seen as early as 2 weeks prior to BTX-A injection. Conclusion: The study demonstrated that the neuropeptide serum is an effective complementary product that can be used with BTX-A treatments to achieve enhanced results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.